ArticleProceedings of the National Academy of Sciences of the United States of America2019

Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

No numbers read from the abstract.

Not cited yet